Sep 2, 2021

Featuring an interview with Dr Kathleen Moore, including the following topics:

• Optimal treatment duration of bevacizumab in combination with paclitaxel/carboplatin for advanced ovarian cancer (0:00)
• Phase III PAOLA-1 trial subgroup analysis: Progression-free survival outcomes by disease stage in patients with newly diagnosed, homologous recombination-deficient advanced ovarian cancer (4:44)
• Efficacy and safety results from the randomized Phase II NEOPEMBROV study assessing neoadjuvant chemotherapy with or without pembrolizumab for patients with advanced high-grade serous carcinoma not eligible for front-line debulking surgery (6:50)
• Combined analysis of Phase III studies assessing the efficacy and safety of niraparib in patients with ovarian cancer with BRCA mutations (11:28)
• Rucaparib versus chemotherapy for relapsed ovarian carcinoma with BRCA mutation in the platinum-sensitive subgroup of patients: Results from the Phase III ARIEL4 study (13:45)
• Clinical activity of olaparib combinations in patients with recurrent PARP inhibitor-resistant cancer: Results from the Phase II CAPRI and EFFORT trials (17:55)
• Efficacy of the combination of mirvetuximab soravtansine and bevacizumab for platinum-agnostic ovarian cancer (25:34)
• Results from the Phase III OUTBACK trial comparing adjuvant chemotherapy after chemoradiation therapy to chemoradiation therapy alone for locally advanced cervical cancer (27:55)
• Clinical data with immunotherapeutic agents for cervical cancer; ongoing Phase III innovaTV 301 study assessing tisotumab vedotin versus chemotherapy for recurrent metastatic cervical cancer (31:14)
• Role of surveillance in the management of endometrial cancer: Results from the TOTEM study (34:51)
• Antitumor activity of dostarlimab alone or in combination with a PARP inhibitor for recurrent endometrial carcinoma (36:51)
• Comparison of health-related quality of life with lenvatinib/pembrolizumab versus chemotherapy for patients with advanced endometrial cancer (39:48)
• Biomarkers of response to immune checkpoint inhibitors; Results from the TAPUR study of dual HER2-targeted therapy for patients with uterine cancer and ERBB2 or ERBB3 abnormalities (41:17)

CME information and select publications